SCHEMBL4550396

SCHEMBL4550396

Cc1cc(C(C)N)cnc1OCC(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 7/20 0.34
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
SCN9A Q15858 2/20 0.33
CYP17A1 P05093 1/20 0.32
C5AR1 P21730 1/20 0.31
SCN4A P35499 3/20 0.30
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
TSHR P16473 1/20 0.30
NFKB1 P19838 1/20 0.30
KCNK3 O14649 1/20 0.30
CACNA1F O60840 1/20 0.30
KCNK2 O95069 1/20 0.30
GBA1 P04062 1/20 0.30
MAOA P21397 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2713841 0.98 AAK1 (0.33) AAK1PIK3CAMTORSCN9ACYP17A1
SCHEMBL4550399 0.83 SCN9A (0.39) SCN9ACYP3A4CYP2C9SCN5A
SCHEMBL3639834 0.82 AAK1 (0.34) AAK1PIK3CAMTOR
SCHEMBL4230736 0.82 AAK1 (0.34) AAK1PIK3CAMTOR
SCHEMBL10290347 0.82 SCN9A (0.34) AAK1SCN9ACYP17A1SLC6A4
SCHEMBL4550848 0.82 PIK3CA (0.36) AAK1PIK3CAMTORSCN9ANFKB1
Hydrochloric Acid SCHEMBL2715279 0.82 SCN9A (0.38) SCN9ACYP3A4CYP2C9SCN5A
SCHEMBL4550341 0.82 MAPT (0.33) PIK3CAMTOR
SCHEMBL4550398 0.81
Hydrochloric Acid SCHEMBL2716910 0.81 PIK3CA (0.36) AAK1PIK3CAMTORSCN9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2841435-B1 PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2017-09-06 EP disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A AAK1 2999/4885PIK3CA 3585/4885MTOR 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.